6Xu XW, Chert YG. Current therapy with nudeoside/nucleotide analogs for patients with chronic hepatitis B[J]. Hepatabiliary Pancreat Dis Int, 2006,5(3):350.
3Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
9Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis, 2006, 26: 162-170.
10Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother, 2004, 48: 3498-3507.
5Rehemann B, Nascimeni M. Immunology of hepatitis B virus and hepatitis C virus infection [ J 1. Nat Rev Immyno1,2005,5 (3) :215 - 229.
6Stroffolini T, Gaeta GB, Mele A. AASLD Practice Guidline Chronic Hepatitis B and HBV infection in Italy [ J ]. Hepatology, 2007,46 (2) :608 -609.
7Chang TT,Jia JD, Omata M. New therapies for chronic hepatitis B in-fection [ J ]. Liver International, 2006,26 ( Suvpl 2 ) : 30.
8European Association For The Study Of The Liver. EA- SL clinical practice guidelines:management of chronic hepatitis B virus infection [ J ]. J Hepatol,2012,57 ( 1 ) : 167 - 185.
9European Association For The Study Of The Liver. EASL clinical practice guidelines., management of chronic hepatitis B virus infection[J]. J Hepatol,2012(57) : 167-185.
10Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia[J]. J Hepatol, 2010(52):508-513.